en · de · es · fr · pt
aod-9604-notes.peptides3081.com › News › Identity And Research Context — Beginner to Advanced

Identity And Research Context — Beginner to Advanced

By Editorial Desk · published 2026-03-11 · last reviewed 2026-04-06 · News

synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Aod-9604 at a glance

PropertyValueNotes
Common nameAOD-9604Development code used in scientific literature.
Chemical classSynthetic peptideFragment of human growth hormone.
Amino acid length16 residuesMatches hGH region 176-191.
AppearanceWhite to off-white powderTypical lyophilized peptide solid.
SolubilitySoluble in waterDissolves in aqueous media; exact behavior depends on salt form.

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Related pages on this site

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Reference notes

Xi's administration enacted a number of changes to the structure of the CCP and state bodies, especially in a large overhaul in 2018. These reforms have been characterized by the integration of CCP and state bodies. Beginning in 2013, the CCP under Xi has created a series of Central Leading Groups: supra-ministerial steering committees, designed to bypass existing institutions when making decisions, and ostensibly make policy-making a more efficient process. Xi was also believed to have diluted the authority of premier Li Keqiang, taking authority over the economy which has generally been considered to be the domain of the premier. February 2014 oversaw the creation of the Central Leading Group for Cybersecurity and Informatization with Xi as its leader. The State Internet Information Office (SIIO), previously under the State Council Information Office (SCIO), was transferred to the central leading group and renamed in English into the Cyberspace Administration of China. As part of managing the financial system, the Financial Stability and Development Committee, a State Council body, was established in 2017. Chaired by vice premier Liu He during its existence, the committee was disestablished by the newly established Central Financial Commission during the 2023 Party and state reforms. Xi has increased the role of the Central Financial and Economic Affairs Commission at the expense of the State Council. 2018 has seen the deepening the reform of the Party and state institutions.

=== Droplet transportation === Discrete droplets can be transported in a highly controlled way using an array of electrodes. In the same way droplets move from an uncharged electrode to a charged electrode, or vice versa, droplets can be continuously transported along the electrodes by sequentially energizing the electrodes. Since droplet transportation involves an array of electrodes, multiple electrodes can be programmed to selectively apply a voltage to each electrode for a better control over transporting multiple droplets.

The RTS,S vaccine was endorsed by the World Health Organization in October 2021 for broad use in children, making it the first malaria vaccine to receive this recommendation. As of April 2022, 1 million children in Ghana, Kenya and Malawi have received at least one shot of the vaccine, with more doses being provided as the vaccine production ramps up. RTS,S reduces hospital admissions from severe malaria by around 30%.

=== Colombia === The Military Forces of Colombia issues the Campaign Ration (Spanish: Ración de Campaña), a dark olive green plastic bag weighing between 1092 and 1205 grams and providing 3,097 to 3,515 kcal (12,960 to 14,710 kJ). Inside are the retort pouch main courses and supplements needed by a soldier for one day. The individual meals, which cater to South American tastes, consist of a breakfast, a lunch, and a main meal (Tamal, envueltos, lentils with chorizo, arvejas con carne, garbanzo beans a la madrileña, arroz atollado, ajiaco con pollo, and sudado con papas y carne). The ration also includes bread products, beverage mixes, candy and accessories. All items except the beverage mixes require no further preparation and can be eaten either hot or cold. The beverage powders must be mixed with hot or cold water before consumption. Each ration also contains raw sugar, a can of condensed milk, sandwich cookies, sweetened and thickened cream spread, hard candy or caramels, peanuts or trail mix or 25 g of roasted almonds, instant coffee, salt, paper towels, a plastic spoon, 2 water purification tablets, and a multivitamin tablet.

Sources: en.wikipedia.org

Reference notes

=== Nonhematopoietic roles === Erythropoietin was reported to have a range of actions beyond stimulation of erythropoiesis including vasoconstriction-dependent hypertension, stimulating angiogenesis, and promoting cell survival via activation of EPO receptors resulting in anti-apoptotic effects on ischemic tissues. However this proposal is controversial with numerous studies showing no effect. It is also inconsistent with the low levels of EPO receptors on those cells. Clinical trials in humans with ischemic heart, neural and renal tissues have not demonstrated the same benefits seen in animals. In addition some research studies have shown its neuroprotective effect on diabetic neuropathy, however these data were not confirmed in clinical trials that have been conducted on the deep peroneal, superficial peroneal, tibial and sural nerves.

== Culinary use == Raw mashua tuber is bitter due to glucosinolates, but the bitterness diminishes after cooking, freezing, or pounding. The tubers comprise as much as 75 percent of the mature plants by dry weight. Popularization of mashua may be limited by its intense flavor and reputation as an anaphrodisiac. Father Bernabé Cobo records that in the 16th century, the Inca used to give enormous amounts of mashua to their troops so that they would forget their wives. However, mashua tubers roasted in traditional earthen field ovens, built at harvest, are considered a delicacy. Also, the raw tubers can be shredded thinly and added to salads to confer a spicy flavor and crunchy texture.

=== Other nitrogen compounds === Chloroplasts make all of a cell's purines and pyrimidines—the nitrogenous bases found in DNA and RNA. They also convert nitrite (NO2−) into ammonia (NH3) which supplies the plant with nitrogen to make its amino acids and nucleotides.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Is AOD-9604 the same as human growth hormone?

No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.

Why is it called hGH fragment 176-191?

The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.

Is AOD-9604 approved for medical use?

No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.

Network